Home/Pipeline/RTIRE Study

RTIRE Study

Favorable Intermediate Risk Prostate Cancer

Feasibility TrialActive

Key Facts

Indication
Favorable Intermediate Risk Prostate Cancer
Phase
Feasibility Trial
Status
Active
Company

About AngioDynamics

AngioDynamics is a publicly traded medical device company with a mission to improve patient lives by providing innovative, minimally invasive tools for treating peripheral vascular disease and cancer. The company has strategically evolved from a broad vascular access provider into a focused innovator, building a diversified technology portfolio through R&D and acquisitions. Its current strategy centers on commercializing and expanding the clinical evidence for its three core platforms—Auryon, AlphaVac, and NanoKnife—while navigating a competitive landscape and managing the financial and operational challenges of a mid-cap device maker.

View full company profile

Therapeutic Areas